Perioperative Organprotektion – Beta-Blocker und Statine

Zusammenfassung

Die perioperative Organfunktionsstörung ist ein Ereignis, dessen Inzidenz zunimmt. Besonders kardiale Ereignisse haben eine große Bedeutung: für die medizinische Betreuung der Patienten und aus ökonomischer Sicht. Hier müssen alle Anstrengungen unternommen werden, um solche Ereignisse zu verhindern. Neben allgemeinen Maßnahmen wie Stressabschirmung, ausreichende Analgesie und suffiziente Volumentherapie stehen die medikamentöse Therapie mit Beta-Adrenozeptor-Antagonisten und HMG-CoA-Reduktase-Inhibitoren im Vordergrund. Beide Medikamentengruppen zeigen pleiotrope Effekte auf die kardiovaskuläre Funktion und reduzieren so die kardiale Morbidität und Mortalität. Daher sollte nach den aktuellen Empfehlungen eine chronische Therapie auf jeden Fall fortgesetzt werden. Ein Neubeginn einer Beta-Blocker-Therapie sollte nur unter individueller Nutzen-Risiko-Abwägung erfolgen, weil eine große aktuelle Studie sowie eine Metaanalyse ein insgesamt schlechteres Outcome bei neu begonnener Beta-Blocker-Therapie im Vergleich zu Plazebo zeigten. Wenn möglich sollte ein solcher Patient solange verschoben werden, bis eine einschleichende Therapie unter Berücksichtigung der Herzfrequenz und des Blutdrucks etabliert werden konnte. Unter Berücksichtigung der aktuellen Datenlage ist auch ein Neubeginn einer perioperativen Statintherapie bei gefäßchirurgischen Patienten zu empfehlen. Für andere Patientengruppen liegen allerdings noch keine Daten vor.

Abstract:

The number of patients with limited organ function is steadily increasing due to the aging of the population. Consequently, a growing number of patients needing surgery is accompanied by serious comorbidities. These patients are at high risk of perioperative organ dysfunction. In this context cardiac events (e.g. cardiac arrhythmias, angina or myocardial infarction) play a major role with significant impact on postoperative care, long term outcome and economic sequelae. Thus, anaesthesiologists must prevent such events in the perioperative period. Besides general measures such as adequate analgesia, protection from stressful events and sufficient volume replacement, medical intervention with beta-blockers or HMG-CoA-reductase-inhibitors (statins) are necessary to reduce the incidence of perioperative cardiac events. Both beta-blockers and HMG-CoA-reductase-inhibitors are known to exhibit pleiotropic effects (defined as additional cardioprotective effects) besides the primary blockade of the beta-adrenergic receptor or the inhibition of the synthesis of serum cholesterol, respectively. Both groups of drugs improve cardiac function, decrease inflammatory response, decrease activation of blood coagulation and stabilize endothelial plaques.

Based on the current literature the following recommendations are published concerning the perioperative administration of beta-blockers: (i) Patients who are on beta-blockers on a regular basis following guidelines concerning chronic treatment of cardiovascular diseases should continue this medication throughout the perioperative period; (ii) a sufficient indicator of an adequate therapy is the baseline heart rate. It should not exceed 60–70bpm at rest; (iii) the Revised Cardiac Risk Index (RCRI) is a widely accepted score to estimate the patient's perioperative cardiac risk; (iv) patients with a RCRI ≥3 should not be scheduled for routine surgery without sufficient beta-adrenergic-receptor blockade; (v) in patients at high cardiac risk based on the RCRI who are scheduled for emergency surgery beta-blocker-therapy should not be initiated de novo perioperatively. However, for perioperative treatment of tachycardia or hypertension beta-blockers are the drug of first choice.

Concerning perioperative statin-therapy the following recommendations are suggested: (i) chronic statin-therapy should be continued throughout surgery and the perioperative period; (ii) in patients without chronic statin-therapy scheduled for vascular surgery this treatment should be started perioperativly; (iii) no data is available concerning other patient populations; (iv) if statin-therapy is indicated it should be started independently from baseline serum LDL-C-concentration; (v) side effects of statin-therapy are rare and usually not live threatening, thus treatment is considered to be without serious risks to the patient.

Kernaussagen

• Eine Million Patienten müssen sich schätzungsweise pro Jahr bei einer zugrundeliegenden KHK einer Operation unterziehen. Die Inzidenz von perioperativen kardialen Ereignissen liegt bei 10–15 % und stellt ein erhebliches medizinisches und volkswirtschaftliches Problem dar.

• Diese Ereignisse sollten verhindert werden durch allgemeine Maßnahmen (Optimierung des Verhältnisses von Sauerstoffangebot zu Sauerstoffverbrauch) und Medikamente.

• Als günstig für das kardiovaskuläre Outcome dieser Risikopatienten haben sich unter bestimmten Bedingungen Beta-Blocker und Statine erwiesen.

• Der Revised-Cardiac-Risk-Index (RCRI) ist im anästhesiologischen Sinne ein praktikabler Score zur Risikoeinschätzung: Mit 6 einfachen Kriterien während der Prämedikation ist er problemlos erfassbar und eine validierte und verbreitete Basis, um die perioperative Versorgung von Risikopatienten zu planen.

• Beta-Blocker wurden trotz umstrittener Studienergebnisse lange Zeit perioperativ auch neu verordnet. Jüngste Ergebnisse einer großen randomisierten Multicenterstudie (POISE) zeigten unter einer neu begonnenen Therapie mit Beta-Blockern eine erhöhte Gesamtmortalität – insbesondere durch vermehrte Schlaganfälle.

• Beta-Blocker werden perioperativ eingesetzt: zur Fortführung einer chronischen Therapie, einschleichend dosiert bei Neubeginn (mehrere Wochen, RCRI ≥ 3) und therapeutisch bei Tachykardie nach Ausschluss anderer Kausalitäten.

• Alternativ oder ergänzend zu Beta-Blockern gibt es HMG-CoA-Reduktase-Inhibitoren (Statine). Aufgrund pleiotroper Effekte (unabhängig von der Fettstoffwechselstörung) beeinflussen sie das kardiale Outcome von Risikopatienten günstig.

• Günstige Effekte einer perioperativen Therapie zeigten sich auch bei kurzfristiger Einnahme, unabhängig von der LDL-C-Serum-Konzentration vor Therapiebeginn.

• Zwei Tatsachen limitieren die Studienergebnisse zur perioperativen Statintherapie: Es gibt nur Daten zu Patienten mit einem gefäßchirurgischen Eingriff, und es fehlen prospektive, randomisierte, plazebokontrollierte Studien.

• Statine haben ein günstiges Nebenwirkungsprofil. Schwerwiegende Komplikationen sind selten.

Literatur

• 1 Rocha PN, Rocha AT, Palmer SM et al.. Acute renal failure after lung transplantation: incidence, predictors and impact on perioperative morbidity and mortality.  Am J Transplant. 2005;  5 1469-1476
• 2 Bernstein WK, Deshpande S.. Preoperative evaluation for thoracic surgery.  Semin Cardiothorac Vasc Anesth. 2008;  12 109-121
• 3 Adesanya AO, de JA Lemos, Greilich NB et al.. Management of perioperative myocardial infarction in noncardiac surgical patients.  Chest. 2006;  130 584-596
• 4 Hughes GC, Landolfo KP, Lowe JE et al.. Perioperative morbidity and mortality after transmyocardial laser revascularization: incidence and risk factors for adverse events.  J Am Coll Cardiol. 1999;  33 1021-1026
• 5 Sweitzer BJ.. Preoperative screening, evaluation, and optimization of the patient's medical status before outpatient surgery.  Curr Opin Anaesthesiol. 2008;  21 711-718
• 6 Mangano DT.. Perioperative cardiac morbidity.  Anesthesiology. 1990;  72 153-184
• 7 Bottiger BW, Martin E.. Prevention of perioperative myocardial ischemia--an update.  Anaesthesist. 2000;  49 174-186
• 8 Archan S, Roscher CR, Fairman RM et al.. Revised Cardiac Risk Index (Lee) and Perioperative Cardiac Events as Predictors of Long-term Mortality in Patients Undergoing Endovascular Abdominal Aortic Aneurysm Repair.  J Cardiothorac Vasc Anesth. 2010;  24 84-90
• 9 Mangano DT, Wong MG, London MJ et al.. Perioperative myocardial ischemia in patients undergoing noncardiac surgery--II: Incidence and severity during the 1st week after surgery. The Study of Perioperative Ischemia (SPI) Research Group.  J Am Coll Cardiol. 1991;  17 851-857
• 10 McCann RL, Clements FM.. Silent myocardial ischemia in patients undergoing peripheral vascular surgery: incidence and association with perioperative cardiac morbidity and mortality.  J Vasc Surg. 1989;  9 583-587
• 11 Wong DH, Hagar JM, Mootz J et al.. Incidence of perioperative myocardial ischemia in TURP patients.  J Clin Anesth. 1996;  8 627-630
• 12 Mackey WC, Fleisher LA, Haider S et al.. Perioperative myocardial ischemic injury in high-risk vascular surgery patients: incidence and clinical significance in a prospective clinical trial.  J Vasc Surg. 2006;  43 533-538
• 13 Bottiger BW, Motsch J, Teschendorf P et al.. Postoperative 12-lead ECG predicts peri-operative myocardial ischaemia associated with myocardial cell damage.  Anaesthesia. 2004;  59 1083-1090
• 14 Badner NH, Knill RL, Brown JE et al.. Myocardial Infarction after Noncardiac Surgery.  1998;  572-578
• 15 Mangano DT, Bottiger BW.. Cardiovascular morbidity and anesthesia.  Anasthesiol Intensivmed Notfallmed Schmerzther. 1995;  30 136-140
• 16 Butte N, Bottiger BW, Teschendorf P.. Perioperative cardioprotection. Golden standard beta-blockade?.  Anaesthesist. 2007;  56 297-298
• 17 Ahmed A.. Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure.  Eur J Heart Fail. 2003;  5 709-715
• 18 Cruickshank JM.. Beta-blockers continue to surprise us.  Eur Heart J. 2000;  21 354-364
• 19 Wikstrand J, Berglund G, Hedblad B et al.. Antiatherosclerotic effects of beta-blockers.  Am J Cardiol. 2003;  91
• 20 Mangano DT, Layug EL, Wallace A et al.. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group.  N Engl J Med. 1996;  335 1713-1720
• 21 Anonymous: Guidelines for assessing and managing the perioperative risk from coronary artery disease associated with major noncardiac surgery. American College of Physicians.  Ann Intern Med. 1997;  127 309-312
• 22 Poldermans D, Boersma E, Bax JJ et al.. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group.  N Engl J Med. 1999;  341 1789-1794
• 23 Slutsky AS, Lavery JV.. Data safety and monitoring boards.  N Engl J Med. 2004;  350 1143-1177
• 24 Bolsin S, Colson M.. Beta blockers for patients at risk of cardiac events during non-cardiac surgery.  Bmj. 2005;  331 919-920
• 25 Juul AB, Wetterslev J, Gluud C et al.. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial.  Bmj. 2006;  332 1482
• 26 Bangalore S, Wetterslev J, Pranesh S et al.. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis.  Lancet. 2008;  372 1962-1976
• 27 Devereaux PJ, Yang H, Yusuf S et al.. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.  Lancet. 2008;  371 1839-1847
• 28 Eagle KA, Berger PB, Calkins H et al.. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery--Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery).  Anesth Analg. 2002;  94 1052-1064
• 29 Fleisher LA, Beckman JA, Brown KA et al.. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology.  Circulation. 2006;  113 2662-2674
• 30 Fleisher LA, Beckman JA, Brown KA et al.. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy--a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery).  Anesth Analg. 2007;  104 15-26
• 31 Mergner D, Rosenberger P, Unertl K et al.. Preoperative evaluation and perioperative management of patients with increased cardiovascular risk.  Anaesthesist. 2005;  54 427-441
• 32 Fleisher LA, Beckman JA, Brown KA et al.. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology.  J Am Coll Cardiol. 2006;  47 2343-2355
• 33 Lee TH, Marcantonio ER, Mangione CM et al.. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery.  Circulation. 1999;  100 1043-1049
• 34 Lindenauer PK, Pekow P, Wang K et al.. Perioperative beta-blocker therapy and mortality after major noncardiac surgery.  N Engl J Med. 2005;  353 349-361
• 35 Beattie WS, Wijeysundera DN, Karkouti K et al.. Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials.  Anesth Analg. 2008;  106 1039-1048
• 36 Libby P.. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization.  Am J Cardiol. 2000;  86
• 37 Libby P.. Multiple mechanisms of thrombosis complicating atherosclerotic plaques.  Clin Cardiol. 2000;  23 3-7
• 38 Ludman A, Venugopal V, Yellon DM et al.. Statins and cardioprotection--more than just lipid lowering?.  Pharmacol Ther. 2009;  122 30-43
• 39 Daumerie G, Fleisher LA. Perioperative beta-blocker and statin therapy.  Curr Opin Anaesthesiol. 2008;  21 60-65
• 40 Hindler K, Eltzschig HK, Fox AA et al.. Influence of statins on perioperative outcomes.  J Cardiothorac Vasc Anesth. 2006;  20 251-258
• 41 Poldermans D, Bax JJ, Kertai MD et al.. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery.  Circulation. 2003;  107 1848-1851
• 42 Blanchard L, Collard CD.. Non-antiarrhythmic agents for prevention of postoperative atrial fibrillation: role of statins.  Curr Opin Anaesthesiol. 2007;  20 53-56
• 43 Feringa HH, Bax JJ, Poldermans D.. Perioperative medical management of ischemic heart disease in patients undergoing noncardiac surgery.  Curr Opin Anaesthesiol. 2007;  20 254-260
• 44 Kertai MD, Boersma E, Westerhout CM et al.. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery.  Eur J Vasc Endovasc Surg. 2004;  28 343-352
• 45 Durazzo AE, Machado FS, Ikeoka DT et al.. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.  J Vasc Surg. 2004;  39 975-976
• 46 Lindenauer PK, Pekow P, Wang K et al.. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery.  Jama. 2004;  291 2092-2099
• 47 Anonymous: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;  360 7-22
• 48 Hindler K, Shaw AD, Samuels J et al.. Improved postoperative outcomes associated with preoperative statin therapy.  Anesthesiology. 2006;  105 1289-1290
• 49 Kapoor AS, Kanji H, Buckingham J et al.. Strength of evidence for perioperative use of statins to reduce cardiovascular risk: systematic review of controlled studies.  Bmj. 2006;  333 1149
• 50 Le Manach Y, Godet G, Coriat P et al.. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery.  Anesth Analg. 2007;  104 1326-1333
• 51 Schouten O, Hoeks SE, Welten GM et al.. Effect of statin withdrawal on frequency of cardiac events after vascular surgery.  Am J Cardiol. 2007;  100 316-320
• 52 Fleisher LA, Beckman JA, Brown KA et al.. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery.  Circulation. 2007;  116 418-499
• 53 Schouten O, Boersma E, Hoeks SE et al.. Fluvastatin and perioperative events in patients undergoing vascular surgery.  N Engl J Med. 2009;  361 980-989
• 54 Pasternak RC, Smith Jr. SC, Bairey-Merz CN et al.. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.  Circulation. 2002;  106 1024-1028
• 55 Laufs U, Custodis F, Bohm M.. HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.  Drugs. 2006;  66 145-154